Michael J. Rybak

Overview

Best Publications

• Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children

  Catherine Liu;Arnold Bayer;Sara E. Cosgrove;Robert S. Daum

  5787
  Citations

• Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications A Scientific Statement for Healthcare Professionals From the American Heart Association

  Larry M. Baddour;Walter R. Wilson;Arnold S. Bayer;Vance G. Fowler

  3598
  Citations

• Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.

  Michael Rybak;Joseph R. Dalovisio

  2365
  Citations

• Therapeutic Monitoring of Vancomycin for Serious Methicillin-resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review by the American Society of Health-system Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists.

  Michael J Rybak;Michael J Rybak;Michael J Rybak;Jennifer Le;Thomas P Lodise;Donald P Levine;Donald P Levine

  1434
  Citations

• Vancomycin Therapeutic Guidelines: A Summary of Consensus Recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists

  Michael J. Rybak;Ben M. Lomaestro;John C. Rotschafer;Robert C. Moellering

  1082
  Citations

• The Pharmacokinetic and Pharmacodynamic Properties of Vancomycin

  Michael J. Rybak

  934
  Citations

• Outcomes Analysis of Delayed Antibiotic Treatment for Hospital-Acquired Staphylococcus aureus Bacteremia

  Thomas P. Lodise;Peggy S. McKinnon;Linda Swiderski;Michael J. Rybak

  788
  Citations

• Impact of Vancomycin Exposure on Outcomes in Patients With Methicillin-Resistant Staphylococcus aureus Bacteremia: Support for Consensus Guidelines Suggested Targets

  Ravina Kullar;Susan L. Davis;Susan L. Davis;Donald P. Levine;Michael J. Rybak;Michael J. Rybak

  637
  Citations

• Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.

  Michael J. Rybak;Michael J. Rybak;Ben M. Lomaestro;John C. Rotschafer;Robert C. Moellering

  564
  Citations

• Prospective Evaluation of the Effect of an Aminoglycoside Dosing Regimen on Rates of Observed Nephrotoxicity and Ototoxicity

  Michael J. Rybak;Michael J. Rybak;Betty J. Abate;S. Lena Kang;Michael J. Ruffing

  520
  Citations

• In Vitro Activities of Daptomycin, Vancomycin, Linezolid, and Quinupristin-Dalfopristin against Staphylococci and Enterococci, Including Vancomycin- Intermediate and -Resistant Strains

  Michael J. Rybak;Ellie Hershberger;Tabitha Moldovan;Richard G. Grucz

  506
  Citations

• Nephrotoxicity of vancomycin, alone and with an aminoglycoside

  Michael J. Rybak;Lisa M. Albrecht;Steven C. Boike;Pranatharthi H. Chandrasekar

  488
  Citations

• Impact of High-Inoculum Staphylococcus aureus on the Activities of Nafcillin, Vancomycin, Linezolid, and Daptomycin, Alone and in Combination with Gentamicin, in an In Vitro Pharmacodynamic Model

  Kerry L. LaPlante;Michael J. Rybak;Michael J. Rybak

  412
  Citations

• Pharmacodynamics of cefepime in patients with Gram-negative infections

  Vincent H. Tam;Peggy S. McKinnon;Ronda L. Akins;Michael J. Rybak

  292
  Citations

• The Importance of Bactericidal Drugs: Future Directions in Infectious Disease

  Robert W. Finberg;Robert C. Moellering;Francis P. Tally;William A. Craig

  291
  Citations

• Ceragenins: cholic acid-based mimics of antimicrobial peptides.

  Xin Zhong Lai;Yanshu Feng;Jacob Pollard;Judy N. Chin

  279
  Citations

• Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations

  Ronda L. Akins;Michael J. Rybak;Michael J. Rybak

  268
  Citations

• A Quasi-Experiment To Study the Impact of Vancomycin Area under the Concentration-Time Curve-Guided Dosing on Vancomycin-Associated Nephrotoxicity.

  Natalie A. Finch;Evan J. Zasowski;Kyle P. Murray;Ryan P. Mynatt

  268
  Citations

• Tigecycline: first of a new class of antimicrobial agents.

  Warren E. Rose;Michael J. Rybak;Michael J. Rybak;Michael J. Rybak

  238
  Citations

• The β-Lactams Strike Back: Ceftazidime-Avibactam.

  Evan J. Zasowski;Jeffrey M. Rybak;Michael J. Rybak;Michael J. Rybak;Michael J. Rybak

  236
  Citations

• Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections.

  A S Benko;D M Cappelletty;J A Kruse;M J Rybak

  230
  Citations

• Early Use of Daptomycin Versus Vancomycin for Methicillin-Resistant Staphylococcus aureus Bacteremia With Vancomycin Minimum Inhibitory Concentration >1 mg/L: A Matched Cohort Study

  Kyle P. Murray;Jing J. Zhao;Susan L. Davis;Ravina Kullar

  229
  Citations